A Phase I Study of PF-06863135 Immunotherapy in Patients with Persistent or Recurrent Multiple Myeloma


Full Title

C1071001: A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, A B-Cell Maturation Antigen (BCMA)- CD3 Bispecific Antibody, As A Single Agent And In Combination With Immunomodulatory Agents In Patients With Relapsed/Refractory Advanced Multiple Myeloma (MM)


The purpose of this study is to find the highest dose of the investigational drug PF-06863135 that can be given safely in patients with multiple myeloma that has continued to grow or came back despite prior treatment. PF-06863135 is an antibody that targets a protein on myeloma cells called BCMA as well as a protein on immune cells (T cells) in the body. By bringing these cells together and activating T cells, PF-06863135 is designed to stimulate immune cells to kill cancer cells. PF-06863135 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma which has continued to grow or came back despite prior therapy.
  • Patients must recover from the serious side effects of previous therapy before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients ages 18 to 69.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Lesokhin at 212-639-3069.





Disease Status

Relapsed or Refractory